SCHEMBL976458

SCHEMBL976458

O=C1CN(N=Cc2ccc(-c3ccc(Cl)cc3Cl)o2)C(=O)N1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INSR P06213 1/20 0.55
IGF1R P08069 1/20 0.55
MAPT P10636 10/20 0.54
LMNA P02545 4/20 0.54
TDP1 Q9NUW8 4/20 0.54
CYP1A2 P05177 3/20 0.54
CYP3A4 P08684 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
CISD1 Q9NZ45 2/20 0.54
ABCB11 O95342 1/20 0.54
ADORA1 P30542 1/20 0.54
GSK3A P49840 1/20 0.53
GSK3B P49841 1/20 0.53
KDM4E B2RXH2 4/20 0.52
HSD17B10 Q99714 2/20 0.52
ABCC4 O15439 1/20 0.52
TP53 P04637 1/20 0.52
TSHR P16473 1/20 0.52
MAOA P21397 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL976457 1.00 INSR (0.55) INSRIGF1RMAPTLMNATDP1
SCHEMBL978317 0.83 MAPT (0.71) MAPTLMNATDP1CYP1A2CYP3A4
SCHEMBL978316 0.83 MAPT (0.71) MAPTLMNATDP1CYP1A2CYP3A4
SCHEMBL16546480 0.82 MAPT (0.60) MAPTLMNATDP1CYP1A2CYP3A4
SCHEMBL16546478 0.82 MAPT (0.60) MAPTLMNATDP1CYP1A2CYP3A4
Clodanolene SCHEMBL122305 0.81 MAPT (0.64) INSRIGF1RMAPTLMNATDP1
Clodanolene SCHEMBL11506877 0.81 MAPT (0.64) INSRIGF1RMAPTLMNATDP1
SCHEMBL16063978 0.76 MAPT (0.71) MAPTLMNATDP1CYP1A2CYP3A4
SCHEMBL976207 0.75 KMT2A (0.71) MAPTLMNATDP1CYP1A2CYP3A4
SCHEMBL16546406 0.75 KMT2A (0.71) MAPTLMNATDP1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975284-B2 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents US WORLDMEDS LLC (US) 2015-03-10 US claimed
US-20110160261-A2 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS US WORLDMEDS, LLC (US) 2011-06-30 US claimed
US-20110015243-A2 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS US WORLDMEDS, LLC (US) 2011-01-20 US claimed
EP-2219605-A1 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS US Worldmeds LLC (US) 2010-08-25 EP claimed
WO-2009048698-A9 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS US WORLDMEDS LLC (US) 2009-11-19 WO claimed
WO-2009048698-A1 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS US WORLDMEDS LLC (US) 2009-04-16 WO claimed
US-20090093531-A1 Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents US WORLDMEDS LLC 2009-04-09 US claimed
US-8975284-B2 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents US WORLDMEDS LLC (US) 2015-03-10 US disclosed
EP-2583670-A1 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents US Worldmeds LLC (US) 2013-04-24 EP disclosed
US-20110160261-A2 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS US WORLDMEDS, LLC (US) 2011-06-30 US disclosed
US-20110015243-A2 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS US WORLDMEDS, LLC (US) 2011-01-20 US disclosed
US-20090093531-A1 Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents US WORLDMEDS LLC 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093531-A1 Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents TERT, TBCA, TTR INSR 2033/4885IGF1R 3778/4885MAPT 677/4885
US-20110160261-A2 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS TERT, TBCA, TTR INSR 2033/4885IGF1R 3778/4885MAPT 677/4885
US-20110015243-A2 CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS TERT, TTR, TTPA INSR 2813/4885IGF1R 3484/4885MAPT 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.